Copyright
©The Author(s) 2017.
World J Gastroenterol. Apr 7, 2017; 23(13): 2396-2403
Published online Apr 7, 2017. doi: 10.3748/wjg.v23.i13.2396
Published online Apr 7, 2017. doi: 10.3748/wjg.v23.i13.2396
Table 3 Virological response after 12 mo of tenofovir disoproxil fumarate therapy according to HBeAg status n (%)
| All | Compensated LC (n = 50) | Decompensated LC (n = 28) | P value | |
| Virological response of HBeAg positive patients (n = 78) | ||||
| Change in serum HBV DNA level | ||||
| Month 6 | -4.32 ± 1.33 | -2.89 | -3.18 | 0.926 |
| Month 12 | -4.65 ± 1.33 | -4.56 ± 1.45 | -4.82 ± 1.08 | 0.701 |
| Serum HBV DNA undetectable | ||||
| Month 6 | 31 (39.7) | 20/50 (40) | 11/17(39.2) | 1.000 |
| Month 12 | 54 (74.3) | 40/10(80) | 14/14(50) | 0.010 |
| Compensated LC (n = 67) | Decompensated LC (n = 29) | |||
| Virological response of HBeAg negative patients (n = 96) | ||||
| Change in serum HBV DNA level | ||||
| Month 6 | -3.86 ± 1.40 | -3.78 ± 1.39 | -4.04 ± 1.43 | 0.576 |
| Month 12 | -4.01 ± 1.37 | -3.94 ± 1.30 | -4.19 ± 1.51 | 0.534 |
| Serum HBV DNA undetectable | ||||
| Month 6 | 65 (67.7) | 47/20 (70.1) | 18/11 (62.0) | 0.481 |
| Month 12 | 90 (93.7) | 64/3 (95.5) | 26/3 (89.6) | 0.362 |
- Citation: Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY, Lee JD. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World J Gastroenterol 2017; 23(13): 2396-2403
- URL: https://www.wjgnet.com/1007-9327/full/v23/i13/2396.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i13.2396